s41568-019-0238-1.pdf (1.35 MB)

A framework for advancing our understanding of cancer-associated fibroblasts.

Download (1.35 MB)
journal contribution
posted on 17.04.2020 by Erik Sahai, Igor Astsaturov, Edna Cukierman, David G DeNardo, Mikala Egeblad, Ronald M Evans, Douglas Fearon, Florian R Greten, Sunil R Hingorani, Tony Hunter, Richard O Hynes, Rakesh K Jain, Tobias Janowitz, Claus Jorgensen, Alec C Kimmelman, Mikhail G Kolonin, Robert G Maki, R Scott Powers, Ellen Puré, Daniel C Ramirez, Ruth Scherz-Shouval, Mara H Sherman, Sheila Stewart, Thea D Tlsty, David A Tuveson, Fiona M Watt, Valerie Weaver, Ashani T Weeraratna, Zena Werb
Cancer-associated fibroblasts (CAFs) are a key component of the tumour microenvironment with diverse functions, including matrix deposition and remodelling, extensive reciprocal signalling interactions with cancer cells and crosstalk with infiltrating leukocytes. As such, they are a potential target for optimizing therapeutic strategies against cancer. However, many challenges are present in ongoing attempts to modulate CAFs for therapeutic benefit. These include limitations in our understanding of the origin of CAFs and heterogeneity in CAF function, with it being desirable to retain some antitumorigenic functions. On the basis of a meeting of experts in the field of CAF biology, we summarize in this Consensus Statement our current knowledge and present a framework for advancing our understanding of this critical cell type within the tumour microenvironment.

Funding

Crick (Grant ID: 10144, Grant title: Sahai FC001144)

History

Licence

Exports

Logo branding

Licence

Exports